MM 11253

CAS No. 345952-44-5

MM 11253( MM-11253 )

Catalog No. M27662 CAS No. 345952-44-5

MM 11253 is a RARγ antagonist with IC50 of 44nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 78 In Stock
5MG 76 In Stock
10MG 122 In Stock
25MG 275 In Stock
50MG 423 In Stock
100MG 625 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    MM 11253
  • Note
    Research use only, not for human use.
  • Brief Description
    MM 11253 is a RARγ antagonist with IC50 of 44nM.
  • Description
    MM 11253 is a RARγ antagonist with IC50 of 44nM.(In Vitro):MM11253 blocks the ability of MM11254 and MM11389 to inhibit squamous cell carcinoma cell growth .
  • In Vitro
    MM11253 blocks the ability of MM11254 and MM11389 to inhibit squamous cell carcinoma cell growth.
  • In Vivo
    ——
  • Synonyms
    MM-11253
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Retinoid Receptor
  • Recptor
    AMPK α2β2γ1|AMPK α1β1γ1|AMPK α2β1γ1|AMPK α1β2γ1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    345952-44-5
  • Formula Weight
    462.67
  • Molecular Formula
    C28H30O2S2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (270.17 mM)
  • SMILES
    CC1(C)CCC(C)(C)c2cc(ccc12)C1(SCCS1)c1ccc2cc(ccc2c1)C(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Zhang LN, et al. Novel small-molecule AMP-activated protein kinase allosteric activator with beneficial effects in db/db mice. PLoS One. 2013 Aug 20;8(8):e72092.
molnova catalog
related products
  • AC-55649

    AC-55649 is a potent and highly isoform-selective agonist of the human RARβ2 receptor, characterized by a pEC50 of 6.9.

  • BMS 753

    BMS 753 is an agonist of isotype-selective retinoic acid receptor α (RARα, Ki= 2 nM).

  • K-8012

    K-8012 is a modulator of the N-terminally truncated RXRα and improves anticancer activities in an RXRα-dependent manner.